142 related articles for article (PubMed ID: 24534569)
1. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia.
Girmenia C; Micozzi A; Piciocchi A; Gentile G; Di Caprio L; Nasso D; Minotti C; Capria S; Cartoni C; Alimena G; Meloni G; Amadori S; Foà R; Venditti A
Leuk Res; 2014 Apr; 38(4):469-74. PubMed ID: 24534569
[TBL] [Abstract][Full Text] [Related]
2. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
3. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
5. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
[TBL] [Abstract][Full Text] [Related]
6. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D
Eur J Haematol; 2008 Nov; 81(5):354-63. PubMed ID: 18637030
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
9. [Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience].
Piatkowska-Jakubas B; Mensah-Glanowska P; Salamańczuk Z; Skotnicki AB
Przegl Lek; 2011; 68(6):291-5. PubMed ID: 22039664
[TBL] [Abstract][Full Text] [Related]
10. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Haznedaroglu IC; Sayınalp N; Aksu S; Ozcebe O; Goker H; Aydın MS; Buyukasık Y
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):729-734. PubMed ID: 31540855
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study.
Egerer G; Geist MJ
Mycoses; 2011 Jan; 54 Suppl 1():7-11. PubMed ID: 21126266
[TBL] [Abstract][Full Text] [Related]
12. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil.
Nucci M; Garnica M; Gloria AB; Lehugeur DS; Dias VC; Palma LC; Cappellano P; Fertrin KY; Carlesse F; Simões B; Bergamasco MD; Cunha CA; Seber A; Ribeiro MP; Queiroz-Telles F; Lee ML; Chauffaille ML; Silla L; de Souza CA; Colombo AL
Clin Microbiol Infect; 2013 Aug; 19(8):745-51. PubMed ID: 23009319
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors.
Wiley JM; Smith N; Leventhal BG; Graham ML; Strauss LC; Hurwitz CA; Modlin J; Mellits D; Baumgardner R; Corden BJ
J Clin Oncol; 1990 Feb; 8(2):280-6. PubMed ID: 2299371
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
18. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
[TBL] [Abstract][Full Text] [Related]
19. A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy.
Kim DY; Lee JH; Sym SJ; Yun SC; Lee JH; Kim SD; Choi Y; Lee YS; Kang YA; Jeon M; Seol M; Lee KH; Lee YJ; Lee KH
Ann Hematol; 2011 Nov; 90(11):1283-91. PubMed ID: 21484304
[TBL] [Abstract][Full Text] [Related]
20. Classification of invasive fungal disease in patients with acute myeloid leukaemia.
Rieger CT; Huppmann S; Peterson L; Rieger H; Ostermann H
Mycoses; 2011 Jul; 54(4):e92-8. PubMed ID: 20202112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
